Cilostazol in Peripheral Artery Disease Management

Indications and Contraindications

The American College of Cardiology recommends cilostazol (100 mg orally twice daily) to improve leg symptoms and increase walking distance in patients with intermittent claudication, not for tissue loss or gangrene 1, 2.
The 2024 ACC/AHA guidelines state that cilostazol improves claudication symptoms and walking distance but make no mention of efficacy in gangrene or tissue necrosis 1.
Cilostazol is absolutely contraindicated in patients with heart failure of any severity, as phosphodiesterase III inhibitors have demonstrated increased mortality in heart failure patients 1, 4.

Cilostazol is a phosphodiesterase III inhibitor that provides vasodilatory and antiplatelet effects by increasing cyclic adenosine monophosphate 3, 4.
The drug's half-life of 11 hours means it requires continuous administration for effect, which is impractical when immediate tissue salvage decisions are needed 3.

Urgent vascular surgery consultation is mandatory to assess for critical limb ischemia and determine if revascularization is feasible before tissue loss progresses 5.
If the limb appears ischemic with dry gangrene, referral to a vascular surgeon is essential, as ischemia is usually due to large-vessel atherosclerosis amenable to angioplasty or bypass 5.
For severely infected ischemic feet, revascularization should be performed early rather than delaying for prolonged antibiotic therapy 5.
Careful debridement of necrotic infected material should not be delayed while awaiting revascularization 5.
Immediate vascular surgery consultation to assess limb viability and revascularization options is recommended for patients presenting with dry gangrene 5.